Hunan Jiudian Pharmaceutical Co., Ltd. (SHE:300705)
China · Delayed Price · Currency is CNY 10.64
-0.24 (-2.21%)
Sep 10, 2026, 12:44 PM CST
SHE:300705 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 5,376 | 7,401 | 8,907 | 11,469 | 8,333 | 8,247 | |
Market Cap Growth | -39.88% | -16.91% | -22.34% | 37.63% | 1.05% | 31.12% |
Enterprise Value | 5,765 | 7,236 | 8,564 | 11,228 | 8,362 | 8,274 |
Last Close Price | 10.88 | 14.49 | 17.02 | 22.30 | 16.15 | 16.50 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 14.23 | 15.65 | 17.38 | 31.14 | 30.90 | 40.38 |
Forward PE | 10.56 | 11.63 | 14.62 | 26.14 | 21.80 | 31.87 |
PS Ratio | 1.86 | 2.38 | 3.04 | 4.26 | 3.58 | 5.07 |
PB Ratio | 1.96 | 2.66 | 3.53 | 5.81 | 5.37 | 7.50 |
P/TBV Ratio | 2.73 | 3.53 | 3.69 | 6.09 | 5.70 | 8.07 |
P/FCF Ratio | 1194.73 | - | 25.56 | 2626.25 | - | 126.98 |
P/OCF Ratio | 7.92 | 11.44 | 11.93 | 26.60 | 30.98 | 43.21 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.00 | 2.33 | 2.92 | 4.17 | 3.60 | 5.08 |
EV/EBITDA Ratio | 10.57 | 10.90 | 13.46 | 25.15 | 24.70 | 31.25 |
EV/EBIT Ratio | 14.64 | 13.31 | 15.81 | 29.93 | 29.99 | 39.17 |
EV/FCF Ratio | 1281.28 | - | 24.57 | 2570.94 | - | 127.41 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.29 | 0.22 | 0.12 | 0.20 | 0.20 | 0.30 |
Debt / EBITDA Ratio | 1.47 | 0.94 | 0.48 | 0.87 | 0.93 | 1.24 |
Debt / FCF Ratio | 178.65 | - | 0.87 | 89.40 | - | 5.06 |
Net Debt / Equity Ratio | 0.09 | 0.00 | -0.16 | -0.06 | -0.08 | -0.15 |
Net Debt / EBITDA Ratio | 0.44 | 0.01 | -0.63 | -0.28 | -0.35 | -0.64 |
Net Debt / FCF Ratio | 52.79 | -1.53 | -1.15 | -28.60 | 0.83 | -2.62 |
Asset Turnover | 0.75 | 0.84 | 0.94 | 1.04 | 1.15 | 1.13 |
Inventory Turnover | 2.20 | 2.36 | 2.50 | 2.46 | 2.29 | 1.99 |
Quick Ratio | 1.67 | 2.67 | 3.01 | 2.76 | 2.12 | 2.12 |
Current Ratio | 2.68 | 3.64 | 4.09 | 3.44 | 2.72 | 2.76 |
Return on Equity (ROE) | 12.50% | 17.69% | 22.77% | 20.89% | 20.34% | 21.11% |
Return on Assets (ROA) | 6.39% | 9.19% | 10.84% | 9.07% | 8.62% | 9.18% |
Return on Invested Capital (ROIC) | 11.71% | 19.73% | 24.41% | 20.94% | 21.94% | 22.20% |
Return on Capital Employed (ROCE) | 10.90% | 15.10% | 18.20% | 15.30% | 15.00% | 15.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 6.34% | 6.39% | 5.75% | 3.21% | 3.24% | 2.48% |
FCF Yield | 0.08% | -0.08% | 3.91% | 0.04% | -1.73% | 0.79% |
Dividend Yield | 3.60% | 2.76% | 1.84% | 1.03% | 1.04% | 0.81% |
Payout Ratio | 52.31% | 34.03% | 22.58% | 25.69% | 25.70% | 7.35% |
Buyback Yield / Dilution | 11.34% | -1.02% | 2.34% | -9.55% | 0.15% | -0.13% |
Total Shareholder Return | 14.94% | 1.74% | 4.18% | -8.53% | 1.19% | 0.68% |